戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 e with 5 x 10(5) focus-forming units of ZIKV intravaginally.
2 esult in viremia in naive females inoculated intravaginally.
3 n sacral ganglia from guinea pigs vaccinated intravaginally.
4  single and repeated doses of MB66 when used intravaginally.
5 eu5Ac9N(3), and CMP-Leg5,7Ac(2) administered intravaginally (10 mug/d) to N. gonorrhoeae-colonized mi
6     On day 17 of gestation mice received LPS intravaginally (10 to 240 mug; n = 3 to 8) or into the u
7 fected with HSV-2 intravaginally and treated intravaginally 24 h later with 100 microg DNA encoding I
8 lt3-L) was found to enhance translocation of intravaginally administered DCs to draining lymph nodes
9                            Here we show that intravaginally administered interleukin 12 (IL-12) encap
10 tics of virus spread, we inoculated macaques intravaginally and euthanized them after 2, 4, 7, and 15
11    When bacterial burdens were equivalent in intravaginally and transcervically infected mice at late
12                     Mice infected with HSV-2 intravaginally and treated intravaginally 24 h later wit
13  intravenously or mucosally (intranasally or intravaginally) and then challenged intravaginally with
14 ted onto the cornea, intramuscularly (i.m.), intravaginally, and intracranially.
15 as shown promise as antiherpetics, including intravaginally applied CpG-containing oligodeoxynucleoti
16                        However, when SEVI is intravaginally applied to living animals, there is no ef
17         We demonstrate that ZOTEN, when used intravaginally as a microbicide, is an effective suppres
18  cells, was detected in all hCD4/R5/cT1 mice intravaginally challenged with an HIV-1 infectious molec
19 ive groups of guinea pigs were immunized and intravaginally challenged with HSV-2.
20               Naive mice given the antiserum intravaginally developed 79% fewer fungal colony-forming
21 eic dendritic cells did not induce responses intravaginally even in ovariectomized mice in the absenc
22 r of the genital tract, rhesus macaques were intravaginally exposed to cell-free simian immunodeficie
23 l, the insertion of pre-cooled magnetic rods intravaginally for short periods over 3 days, reduced th
24             Female BALB/c mice were infected intravaginally (i.v.), intranasally (i.n.), orally (p.o.
25 onses were compared in female mice immunized intravaginally (i.vag.) or intranasally (i.n.) with a ba
26 , BALB/c or congenic SCID mice were infected intravaginally (i.vag.) with the HSV type 2 (HSV-2) vhs
27 to either peptide Ag or male cells delivered intravaginally in ovariectomized mice, but this response
28 ls, bacteria were inoculated in mouse either intravaginally in the last trimester of pregnancy or sys
29 itope (gB(498-505)), and both were delivered intravaginally in the progesterone-induced B6 mouse mode
30                                           In intravaginally infected guinea pigs, HSV2-LAT-E1 reactiv
31 amydia-infected mice, and in initial studies intravaginally infected wild-type, IL-10(-/-), IL-4(-/-)
32          In the current study, 27 of 40 mice intravaginally infected with Chlamydia muridarum develop
33 rol of a CD4 promoter (JR-CSF/hu-cycT1) were intravaginally infected with HSV-2 and evaluated for dis
34                             Guinea pigs were intravaginally infected with HSV-2 and then were randomi
35                               The CBA/J mice intravaginally infected with the same plasmid-free C. mu
36                                              Intravaginally inoculated animals died within 6 months,
37 ravenous inoculation and a week later in the intravaginally inoculated animals.
38 ) T cells followed by development of AIDS in intravaginally inoculated macaques and thus provides a h
39 tics of retroviral recombination in vivo, we intravaginally inoculated rhesus macaques, either simult
40 e with pathogenic SIV, all five animals were intravaginally inoculated twice with pathogenic SIV-mac2
41 (-/-), IL-17RA(-/-) and IL-22(-/-) mice were intravaginally inoculated with Candida, and vaginal lava
42  was eventually found in four of six animals intravaginally inoculated with the two SIVmac239 deletio
43 1 (HIV-1) env/rev and gag/pol were delivered intravaginally (IVAG) and intramuscularly (IM) to 2 preg
44  while two additional adult female AGMs were intravaginally (IVAG) exposed.
45 us macaques inoculated intravenously (IV) or intravaginally (IVAG) with a genetically heterogeneous S
46 arious mucosal routes-oral, intrarectal, and intravaginally (ivag)-followed by a systemic or mucosal
47         Pregnant BALB/c mice were inoculated intravaginally on day 5 of gestation with the Chlamydia
48 sis of tissues of rhesus macaques inoculated intravaginally or i.v. with SIV supports the proposed ro
49 ce were inoculated with these strains either intravaginally or transcervically.
50  used to quantify lachrymal secretions, were intravaginally placed in untreated ovary-intact mice, DM
51 HeJ mice were either sham or INP0341 treated intravaginally pre- and postinoculation with 5 x 10(2) i
52   In this study, a therapeutic vaccine given intravaginally resulted in significantly better protecti
53 l mucosa, while the same antibodies injected intravaginally significantly reduced Thy-1+ T cells in b
54 in which female rhesus macaques were exposed intravaginally to a high dose of simian immunodeficiency
55                                 When applied intravaginally to humanized mice, CD4-AsiCs protected ag
56 re significantly greater in macaques exposed intravaginally to lower rather than higher inoculum dose
57 10(6)- or 10(8)-cfu CTV-05 capsules inserted intravaginally twice daily for 3 days.
58 served only in macaques that were challenged intravaginally twice within the same day with a high dos
59          Groups of guinea pigs were infected intravaginally with 10(4), 10(3), 10(2), and 10(1) inclu
60 nnate immunity-deficient C3H/HeJ female mice intravaginally with a human serovar D urogenital isolate
61                              Mice inoculated intravaginally with a lethal dose of HSV-2, and treated
62 pre-treated with progesterone and inoculated intravaginally with artificial insemination fluid from Z
63 lowing immunization, animals were challenged intravaginally with C. muridarum.
64 l 12:12 light: dark (LD) cycle were infected intravaginally with Chlamydia muridarum either at zeitge
65 emale C3H/HeN and C57BL/6 mice were infected intravaginally with Chlamydia muridarum.
66  into syngeneic naive animals and challenged intravaginally with Chlamydia, recipients of IM immuniza
67 mia, nonobese diabetic (NOD) mice inoculated intravaginally with clinical C. glabrata isolates were s
68 protein, delivered either intramuscularly or intravaginally with CpG and alum adjuvants, (i) boosted
69 g from 5 to 14 weeks of age, were inoculated intravaginally with different doses of the Chlamydia tra
70  Chlamydia trachomatis, mice were challenged intravaginally with either MoPn or human serovar E or L2
71 t this hypothesis, we treated rhesus monkeys intravaginally with either the TLR9 agonist, CpG oligode
72 and selected chemokines/cytokine and boosted intravaginally with gp140 recombinant protein.
73 2Rgamma(-/-)) (NSG)-BLT mice were inoculated intravaginally with HIV and were monitored for plasma vi
74  or the licensed HPV vaccines and challenged intravaginally with HPV6, HPV16, HPV26, HPV31, HPV33, HP
75 O 2000 gel protected 100% of mice challenged intravaginally with HSV-2 introduced in PBS, whereas onl
76 vaccine FENDrix) and subsequently challenged intravaginally with HSV-2 or HSV-1.
77 a pigs immunized and subsequently challenged intravaginally with HSV-2.
78 e mice were immunized either intranasally or intravaginally with live elementary bodies (EB).
79 rogesterone or estradiol and then inoculated intravaginally with M. genitalium type strain G37 or a c
80                          Macaques challenged intravaginally with pathogenic simian immunodeficiency v
81 sally or intravaginally) and then challenged intravaginally with pathogenic SIVmac239.
82 ult female macaques that had been inoculated intravaginally with pathogenic SIVmac251 became transien
83 lowing vaccination, macaques were challenged intravaginally with repeated weekly low doses of SIV(mac
84 PGT121 to rhesus monkeys and challenged them intravaginally with SHIV-SF162P3.
85 (controls; n = 7) were repeatedly challenged intravaginally with SHIVSF162p3.
86 ciency virus (SHIV) 89.6 and then challenged intravaginally with SIVmac239 controlled viral replicati
87  Four female rhesus macaques were inoculated intravaginally with SIVmac251, and then killed 2, 5, 7,
88 e TNF-alpha response in guinea pigs infected intravaginally with the guinea pig strain of Chlamydia p
89 feron gamma gene-deficient C57 mice infected intravaginally with the mouse pneumonitis agent of Chlam
90        A susceptible strain of mice infected intravaginally with the mouse pneumonitis biovar of Chla
91 L/6), treated with progesterone and infected intravaginally with the mouse pneumonitis strain of Chla
92 R2) protein (Prime) and subsequently treated intravaginally with the neurotropic adeno-associated vir
93  model, rhesus macaques (RM) were inoculated intravaginally with two or three HSV-2 strains (186, 333
94 oth B7-1 and B7-2 (B7KO mice), when infected intravaginally with virulent herpes simplex virus type 2
95                           B7KO mice infected intravaginally with virulent HSV-2 showed more severe ge
96 reated with 17-beta-estradiol and inoculated intravaginally with wild-type gonococcal strain FA1090 o
97 ceptibility to N. gonorrhoeae and inoculated intravaginally with wild-type gonococci or a catalase (k
98 asma vRNA levels seen for monkeys inoculated intravaginally with wt SIVmac239.
99 highly attenuated in wild-type mice infected intravaginally, with reduced mucosal replication, diseas